The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million that Nestle had already invested in Aimmune, Nestle said in a statement.from Moneycontrol Business News https://ift.tt/2QEFiGF
Monday, August 31, 2020
Nestle to buy Aimmune Therapeutics, valuing allergy treatment maker at $2.6 billion
The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million that Nestle had already invested in Aimmune, Nestle said in a statement.from Moneycontrol Business News https://ift.tt/2QEFiGF
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The EUA will facilitate broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease, enabling access to remdesivi...
No comments:
Post a Comment